# Adavosertib and Gemcitabine in Advanced Pancreatic

> **NCT05212025** · PHASE2 · WITHDRAWN · sponsor: **James Cleary, MD, PhD**

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Adavosertib
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT05212025
- **Lead sponsor:** James Cleary, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-06
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** manufacturer choice
- **Last updated:** 2022-06-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05212025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05212025, "Adavosertib and Gemcitabine in Advanced Pancreatic". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05212025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*